Tumour angiogenesis: a novel therapeutic target in patients with malignant disease.

about

Genetic variations in regulator of G-protein signaling genes as susceptibility loci for second primary tumor/recurrence in head and neck squamous cell carcinoma.Platelet "first responders" in wound response, cancer, and metastasis.

P2860

Q34180253-85BADC6D-3568-4593-98F7-61AF05F3E26F Q39449769-70DC92DD-DA17-4451-B6EE-762848976492

P2860

Tumour angiogenesis: a novel therapeutic target in patients with malignant disease.

Item

http://www.wikidata.org/entity/Q46576599

description

2001 nî lūn-bûn

@nan

2001年の論文

@ja

2001年学术文章

@wuu

2001年学术文章

@zh

2001年学术文章

@zh-cn

2001年学术文章

@zh-hans

2001年学术文章

@zh-my

2001年学术文章

@zh-sg

2001年學術文章

@yue

2001年學術文章

@zh-hant

name

Tumour angiogenesis: a novel therapeutic target in patients with malignant disease.

@en

Tumour angiogenesis: a novel therapeutic target in patients with malignant disease.

@nl

type

Item

label

Tumour angiogenesis: a novel therapeutic target in patients with malignant disease.

@en

Tumour angiogenesis: a novel therapeutic target in patients with malignant disease.

@nl

prefLabel

Tumour angiogenesis: a novel therapeutic target in patients with malignant disease.

@en

Tumour angiogenesis: a novel therapeutic target in patients with malignant disease.

@nl

P1476

Tumour angiogenesis: a novel therapeutic target in patients with malignant disease.

@en

P2093

O'Byrne KJ

http://www.w3.org/2001/XMLSchema#string

Steward WP

http://www.w3.org/2001/XMLSchema#string

P2860

Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2.

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

Interleukin 6 induces the expression of vascular endothelial growth factor

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

Thalidomide is an inhibitor of angiogenesis

The vitronectin receptor and its associated CD47 molecule mediates proinflammatory cytokine synthesis in human monocytes by interaction with soluble CD23

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

P304

155-174

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14728214.6.1.155

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2001-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15989502

http://www.w3.org/2001/XMLSchema#string

Tumour angiogenesis: a novel therapeutic target in patients with malignant disease.

about

P2860

P2860

Tumour angiogenesis: a novel therapeutic target in patients with malignant disease.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698